Results 211 to 220 of about 43,637 (267)

Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation. [PDF]

Clin Pharmacokinet
Lai NS, Lin CJ, Kuo CH, Peng YF, Tang SC, Huang CF, Lin SY, Lin SW.   +7 more
europepmc   +1 more source

Effect of oxycodone vs. morphine as first‐line opioid on new persistent opioid use after orthopaedic surgery: A prospective sequential cohort study

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2693-2700, August 2026.
Abstract Background Postoperative opioids, intended for short‐term analgesia, contribute to new persistent opioid use in 1%–7% of patients, adversely affecting outcomes. Oxycodone may carry higher risk than morphine, though long‐term data are limited.
Eward J. Melis, Johanna E. Vriezekolk, Frédérique H. C. Bollen, Dirk E. Schrander, Arnt F. A. Schellekens, Bart J. F. van den Bemt   +5 more
wiley   +1 more source

Impact of CYP and ABCB1 Polymorphisms on Bortezomib-Induced Adverse Events in Multiple Myeloma. [PDF]

Biomedicines
Sanz-Solas A, Pérez-Gómez N, Labrador J, Cuevas B, Cuevas MV, Díaz-Gálvez FJ, Hermida G, Álvarez-Nuño R, Benzo G, Alonso-Madrigal C, González-Oter M, García-Sancha N, Vinuesa R, Rodríguez-Lopez A, Novalbos J, Busto N, Alcaraz R, Abad-Santos F, Saiz-Rodríguez M.   +18 more
europepmc   +1 more source

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2764-2776, August 2026.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf, Ymke van der Velde, Paul R. V. Malik, Jelmer R. Prins, Sanne J. Gordijn, Daan J. Touw, Paola Mian   +6 more
wiley   +1 more source

Mechanistic insights into atorvastatin-induced hepatotoxicity: molecular pathways, clinical relevance, and strategies for safer personalized therapy. [PDF]

Clin Exp Med
Abdel-Rasol MA, El-Sayed WM.
europepmc   +1 more source

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2863-2873, August 2026.
Aims This work aimed to correlate potential links between the suspected adverse drug reaction (ADR) profile of licensed nonsteroidal androgen receptor antagonists (NSARA) with their unique chemical properties and known off‐target polypharmacology. Methods Physicochemical and polypharmacology data were curated from the Electronic Medicines Compendium ...
Simrit Dhillon, Albert A. Antolin, Alan M. Jones   +2 more
wiley   +1 more source

Mechanistic insights into voriconazole-exacerbated selpercatinib-induced thrombocytopenia: a pharmacokinetic interaction case report. [PDF]

Front Oncol
Tang H, Zhou Z, Zhang Y, Chen W, Meng J, Li G.   +5 more
europepmc   +1 more source

Optimized SPE‐HPLC‐FLD Method for the Simultaneous Determination of Olaparib, Propranolol, and Furosemide in Human Urine

Biomedical Chromatography, Volume 40, Issue 8, August 2026.
ABSTRACT Olaparib belongs to the PARP inhibitors and is widely used as an anticancer drug. Due to frequent side effects, it is usually co‐administered with an antihypertensive, such as propranolol and/or an antidiuretic, such as furosemide. In this study, a highly sensitive HPLC‐FLD method was developed for the simultaneous determination of the three ...
Georgios Kamaris, Antonia Kalagia, Catherine K. Markopoulou   +2 more
wiley   +1 more source

Lipid Dependence of CYP3A4 Activity in Nanodiscs. [PDF]

Biology (Basel)
Denisov IG, Grinkova YV, Sligar SG.
europepmc   +1 more source

Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score‐Matched Real‐World Analysis

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Bruton tyrosine kinase inhibitors are central to the treatment of relapsed or refractory mantle cell lymphoma, but cardiovascular and bleeding toxicities influence treatment selection. Ibrutinib has been associated with atrial fibrillation/flutter and other cardiovascular adverse events, whereas second‐generation covalent BTK ...
Anna Homeniuk, Amrit Sandhu, Leena Abdalla, Anas Atrash   +3 more
wiley   +1 more source